The investment will be used to help increase enrollment of follicular lymphoma patients in an ongoing Phase I study of Verismo's KIR-CAR therapy.

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced an ag ...

German regulatory agency, the Paul Ehrlich Institute, granted approval to expand the INVISE Phase 1 clinical trial evaluating INT2104 for the treatment of B-cell malignancies to Europe The first ...

Cell therapies have suffered from hyped-up expectations, clinical setbacks and high costs. But maybe, just maybe, Arovella is ...

Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivoPrograms to focus on ...

WITH cases of flu rising across the UK this winter, personal trainers have shared a quick, 15-minute workout, after research ...

In addition, on January 1, 2025, the Company also received an additional $1.5 million from its $8 million gant from the California Institute for Regenerative Medicines (“CIRM”) that was first ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common ...

Instead, we're recruiting healthy soldiers from disease-free, well donors and equipping them with special targeting systems ...